treatment multiple sclerosis m chang last year immunotherapeut drug target recaps remit arm still remain medic challenge develop progress form common inject diseasemodifi therapy include Î²interferon b glatiram act howe one major challenge poor adhere approx patient discontinue therapy within first year herein go back basic understand immunopathophysiolog gain insight develop new improv drug treatment present current interferon dimethyl kumar teriflunomid fingolimod mitoxantron human monoclonal antibody natalizumab ofatumumab ocrelizumab alemtuzumab daclizumab emerge immune model approach stem cell dna vaccine nanoparticles alter peptide ligand 